Article Text

Download PDFPDF
Letter
Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis
  1. Hanno Ehlken1,2,
  2. Raluca Wroblewski1,
  3. Christophe Corpechot3,
  4. Lionel Arrivé4,5,
  5. Susanne Lezius6,
  6. Johannes Hartl1,
  7. Ulrike W Denzer2,
  8. Ansgar W Lohse,
  9. Olivier Chazouilleres3,
  10. Christoph Schramm1
  1. 1 1st Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  2. 2 Department of Interdisciplinary Endoscopy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  3. 3 AP-HP, Hôpital Saint-Antoine, Service d'Hépatologie, Reference Center for Inflammatory Biliary Diseases, Sorbonne Universités, UPMC Univ Paris 06, UMR_S 938, Paris, France
  4. 4 Department of Radiology, Saint-Antoine Hospital, Paris, France
  5. 5 Pierre and Marie Curie University—Paris 6. Faculté de médecine Pierre et Marie Curie, Paris France
  6. 6 Department of Medical Biometry and Epidemiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
  1. Correspondence to Professor Christoph Schramm, I. Department of Medicine, Helmut and Hannelore Greve Foundation Chair for Rare Diseases, Martin Zeitz-Centre for Rare Diseases, Martinistr. 52, Hamburg 20246, Germany; c.schramm{at}uke.de

Statistics from Altmetric.com

Dear Sir,

We read with interest the work of van der Meer et al1 who propose a risk score for patients with chronic Hepatitis C. The authors demonstrate that the assessment of readily available and objective parameters can stratify patients according to the risk of disease progression. Patients with primary sclerosing cholangitis (PSC) usually develop progressive liver fibrosis and end-stage liver disease within 10–20 years.2 Simple and non-invasive means for disease stratification and prediction of prognosis are urgently needed. Indeed, the International PSC Study Group recently declared the research on surrogate end-point markers as a high-priority task,3 since several clinical studies investigating novel treatment strategies …

View Full Text

Footnotes

  • Contributors HE, RW, UWD and JH acquired data. CC, LA and OC acquired data from the Paris cohort. SL calculated statistics. HE, CC, LA, OC, AWL and CS interpreted data. All authors approved the final manuscript.

  • Funding The study was supported by the Deutsche Forschungsgemeinschaft (SFB841 and KFO306), the YAEL-Foundation and the Helmut and Hannelore Greve Foundation.

  • Competing interests None declared.

  • Ethics approval Hamburg ethical review board (OB-17/06), Comité de protection des personnes, Ile de France V, 02/04/2013.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.